|
1
|
Carneiro RM, Carneiro BA, Agulnik M, Kopp
PA and Giles FJ: Targeted therapies in advanced differentiated
thyroid cancer. Cancer Treat Rev. 41:690–698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tuttle RM: Controversial issues in thyroid
cancer management. J Nucl Med. 59:1187–1194. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bates MF, Lamas MR, Randle RW, Long KL,
Pitt SC, Schneider DF and Sippel RS: Back so soon? Is early
recurrence of papillary thyroid cancer really just persistent
disease? Surgery. 163:118–123. 2018.PubMed/NCBI
|
|
6
|
Zhang H and Hu N: Telomerase reverse
transcriptase induced thyroid carcinoma cell proliferation through
PTEN/AKT signaling pathway. Mol Med Rep. 18:1345–1352. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grimshaw MJ: Endothelins and
hypoxia-inducible factor in cancer. Endocr Relat Cancer.
14:233–244. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubanyi GM and Polokoff MA: Endothelins:
Molecular biology, biochemistry, pharmacology, physiology, and
pathophysiology. Pharmacol Rev. 46:325–415. 1994.PubMed/NCBI
|
|
9
|
Grimshaw MJ, Hagemann T, Ayhan A, Gillett
CE, Binder C and Balkwill FR: A role for endothelin-2 and its
receptors in breast tumor cell invasion. Cancer Res. 64:2461–2468.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smollich M and Wülfing P: The endothelin
axis: A novel target for pharmacotherapy of female malignancies.
Curr Vasc Pharmacol. 5:239–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pollock DM, Keith TL and Highsmith RF:
Endothelin receptors and calcium signaling. FASEB J. 9:1196–1204.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bagnato A and Catt KJ: Endothelins as
autocrine regulators of tumor cell growth. Trends Endocrinol Metab.
9:378–383. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bagnato A, Spinella F and Rosanò L:
Emerging role of the endothelin axis in ovarian tumor progression.
Endocr Relat Cancer. 12:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bagnato A and Rosanò L: The endothelin
axis in cancer. Int J Biochem Cell Biol. 40:1443–1451. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Irani S, Salajegheh A, Smith RA and Lam
AK: A review of the profile of endothelin axis in cancer and its
management. Crit Rev Oncol Hematol. 89:314–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tilly N, Schneider JG, Leidig-Bruckner G,
Sommer U and Kasperk C: Endothelin-1 levels in patients with
disorders of the thyroid gland. Exp Clin Endocrinol Diabetes.
111:80–84. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Donckier JE, Michel L, Delos M, Havaux X
and Van Beneden R: Interrelated overexpression of endothelial and
inducible nitric oxide synthases, endothelin-1 and angiogenic
factors in human papillary thyroid carcinoma. Clin Endocrinol
(Oxf). 64:703–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Irani S, Salajegheh A, Gopalan V, Smith RA
and Lam AK: Expression profile of endothelin 1 and its receptor
endothelin receptor A in papillary thyroid carcinoma and their
correlations with clinicopathologic characteristics. Ann Diagn
Pathol. 18:43–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Olender J, Nowakowska-Zajdel E,
Kruszniewska-Rajs C, Orchel J, Mazurek U, Wierzgoń A, Kokot T and
Muc-Wierzgoń M: Epigenetic silencing of endothelin-3 in colorectal
cancer. Int J Immunopathol Pharmacol. 29:333–340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Löhr CV, Fischer K, Dashwood WM,
Greenwood JA, Ho E, Williams DE, Ashktorab H, Dashwood MR and
Dashwood RH: Epigenetic inactivation of endothelin-2 and
endothelin-3 in colon cancer. Int J Cancer. 132:1004–1012. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wiesmann F, Veeck J, Galm O, Hartmann A,
Esteller M, Knüchel R and Dahl E: Frequent loss of endothelin-3
(EDN3) expression due to epigenetic inactivation in human breast
cancer. Breast Cancer Res. 11:R342009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Ye F, Yamada K, Tso JL, Zhang Y,
Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, et al: Autocrine
endothelin-3/endothelin receptor B signaling maintains cellular and
molecular properties of glioblastoma stem cells. Mol Cancer Res.
9:1668–1685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiu J, Zhang W, Zang C, Liu X, Liu F, Ge
R, Sun Y and Xia Q: Identification of key genes and miRNAs markers
of papillary thyroid cancer. Biol Res. 51:452018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Q, Wang S, Wang H, Li P and Ma Z:
MicroRNAs: Novel biomarkers for lung cancer diagnosis, prediction
and treatment. Exp Biol Med (Maywood). 237:227–235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Z, Sha HH and Li HJ: Functions and
mechanisms of miR-186 in human cancer. Biomed Pharmacother.
119:1094282019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu L, Deng H, Hu J, Huang S, Xiong J and
Deng J: The promising role of miR-296 in human cancer. Pathol Res
Pract. 214:1915–1922. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iacona JR and Lutz CS: miR-146a-5p:
Expression, regulation, and functions in cancer. Wiley Interdiscip
Rev RNA. 10:e15332019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanellopoulou C and Monticelli S: A role
for microRNAs in the development of the immune system and in the
pathogenesis of cancer. Semin Cancer Biol. 18:79–88. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Irmak-Yazicioglu MB: Mechanisms of
MicroRNA deregulation and MicroRNA targets in gastric cancer. Oncol
Res Treat. 39:136–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu T, Ma P, Wu D, Shu Y and Gao W:
Functions and mechanisms of microRNA-31 in human cancers. Biomed
Pharmacother. 108:1162–1169. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yan X, Yu H, Liu Y, Hou J, Yang Q and Zhao
Y: miR-27a-3p functions as a tumor suppressor and regulates
non-small cell lung cancer cell proliferation via targeting HOXB8.
Technol Cancer Res Treat. 18:15330338198619712019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li JM, Zhou J, Xu Z, Huang HJ, Chen MJ and
Ji JS: MicroRNA-27a-3p inhibits cell viability and migration
through down-regulating DUSP16 in hepatocellular carcinoma. J Cell
Biochem. 119:5143–5152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: MiR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liang J, Tang J, Shi H, Li H, Zhen T, Duan
J, Kang L, Zhang F, Dong Y and Han A: miR-27a-3p targeting RXRalpha
promotes colorectal cancer progression by activating
Wnt/beta-catenin pathway. Oncotarget. 8:82991–83008. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li E, Han K and Zhou X: microRNA-27a-3p
down-regulation inhibits malignant biological behaviors of ovarian
cancer by targeting BTG1. Open Med (Wars). 14:577–585. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu XZ, Wang KP, Song HJ, Xia JH, Jiang Y
and Wang YL: MiR-27a-3p promotes esophageal cancer cell
proliferation via F-box and WD repeat domain-containing 7 (FBXW7)
suppression. Int J Clin Exp Med. 8:15556–15562. 2015.PubMed/NCBI
|
|
38
|
Wang YL, Gong WG and Yuan QL: Effects of
miR-27a upregulation on thyroid cancer cells migration, invasion,
and angiogenesis. Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maqbool R, Lone SN and Ul Hussain M:
Post-transcriptional regulation of the tumor suppressor p53 by a
novel miR-27a, with implications during hypoxia and tumorigenesis.
Biochem J. 473:3597–3610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li P, Zhang Q and Tang H: INPP1
up-regulation by miR-27a contributes to the growth, migration and
invasion of human cervical cancer. J Cell Mol Med. 23:7709–7716.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li L and Luo Z: Dysregulated miR-27a-3p
promotes nasopharyngeal carcinoma cell proliferation and migration
by targeting Mapk10. Oncol Rep. 37:2679–2687. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tang H, Xu X, Xiao W, Liao Y, Xiao X, Li
L, Li K, Jia X and Feng H: Silencing of microRNA-27a facilitates
autophagy and apoptosis of melanoma cells through the activation of
the SYK-dependent mTOR signaling pathway. J Cell Biochem.
120:13262–13274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shang D, Xie C, Hu J, Tan J, Yuan Y, Liu Z
and Yang Z: Pancreatic cancer cell-derived exosomal microRNA-27a
promotes angiogenesis of human microvascular endothelial cells in
pancreatic cancer via BTG2. J Cell Mol Med. 24:588–604. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nelson J, Bagnato A, Battistini B and
Nisen P: The endothelin axis: Emerging role in cancer. Nat Rev
Cancer. 3:110–116. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen LL, Zhu J, Schumacher J, Wei C,
Ramdas L, Prieto VG, Jimenez A, Velasco MA, Tripp SR, Andtbacka
RHI, et al: SCF-KIT signaling induces endothelin-3 synthesis and
secretion: Thereby activates and regulates endothelin-B-receptor
for generating temporally- and spatially-precise nitric oxide to
modulate SCF- and or KIT-expressing cell functions. PLoS One.
12:e01841542017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Alcendor DJ: Dysregulation of
endothelin-1: Implications for health disparities in Alzheimer's
disease. J Pers Med. 10:1992020. View Article : Google Scholar
|
|
48
|
Davenport AP, Hyndman KA, Dhaun N, Southan
C, Kohan DE, Pollock JS, Pollock DM, Webb DJ and Maguire JJ:
Endothelin. Pharmacol Rev. 68:357–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aydin AF, Vural P, Doğru-Abbasoğlu S and
Çil E: The endothelin 1 and endothelin receptor A gene
polymorphisms increase the risk of developing papillary thyroid
cancer. Mol Biol Rep. 46:199–205. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kang BY, Park K, Kleinhenz JM, Murphy TC,
Sutliff RL, Archer D and Hart CM: Peroxisome proliferator-activated
receptor γ regulates the V-Ets avian erythroblastosis virus E26
oncogene homolog 1/microRNA-27a axis to reduce endothelin-1 and
endothelial dysfunction in the sickle cell mouse lung. Am J Respir
Cell Mol Biol. 56:131–144. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xie X, Li S, Zhu Y, Liu L, Pan Y, Wang J,
Shi W, Song Y, Yang L, Gao L, et al: MicroRNA-27a/b mediates
endothelin-1-induced PPARγ reduction and proliferation of pulmonary
artery smooth muscle cells. Cell Tissue Res. 369:527–539. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kang BY, Park KK, Green DE, Bijli KM,
Searles CD, Sutliff RL and Hart CM: Hypoxia mediates mutual
repression between microRNA-27a and PPARγ in the pulmonary
vasculature. PLoS One. 8:e795032013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lin H, Ma Y, Wei Y and Shang H:
Genome-wide analysis of aberrant gene expression and methylation
profiles reveals susceptibility genes and underlying mechanism of
cervical cancer. Eur J Obstet Gynecol Reprod Biol. 207:147–152.
2016. View Article : Google Scholar : PubMed/NCBI
|
